HEALTH CARE
- Share via
Divide and Conquer: Cytocare Inc., an Irvine medical device manufacturer, is diversifying when others are consolidating.
The company, which already has one wholly owned subsidiary that manufactures a machine that pulverizes kidney stones, is splitting into three divisions to oversee its diversification efforts more carefully.
Under its endourology division, the company will sell its line of catheters and lasers for use in opening blockages of the prostate gland.
Its medical biology division is developing ways to diagnose prostate cancer and other diseases, while a third division, the small molecule pharmaceuticals division, is working on new drugs to treat prostate cancer and other prostate diseases, such as enlargement of the prostate.
“We have tried to position ourselves not only to continue to provide good science, but to respond to the reformation of the health care system under the Clinton Administration,” said Cytocare Chief Executive Errol Payne.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
